Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Reply

Dear Editor, We thank Drs Mazumder and Mukhtyar for their positive commentary [1] on our paper [2]. It is increasingly recognized that GCA is a heterogeneous disease on the basis not only of clinical phenotypes, but also of immunopathological characteristics. Similar to your thoughts, we propose that future research efforts focus on all these aspects of the disease to map the distinct endotypes and, ultimately, carve the path towards precision medicine in GCA. Although there is emerging evidence to support the distinct subsets within the spectrum of GCA, these observations require validation in multicentre studies, and further research efforts are required to explore in depth the immunobiological drivers of these disease endotypes.